Skip to content

KLRS KLRS Deferred Transaction And Financing Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities

Deferred Transaction And Financing Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities at other companies

Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$7.5K
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0-100%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$202K
Rumble, Inc. logo
Rumble, Inc.RUM
$220K
NetSTREIT logo
NetSTREITNTST
$502K+1,992%
Teads Holding Co. Common Stock logo
Teads Holding Co. Common StockTEAD
$0-100%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept klrs:DeferredTransactionAndFinancingIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities?
KLRS (KLRS) reported deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities of $337K in Q1 2026.
How has KLRS's deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities changed year-over-year?
KLRS's deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities decreased by 46.4% year-over-year, from $629K to $337K.
What does deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities mean?
Represents transaction-related costs that have been accrued but not yet paid, typically recorded within current liabilities. These costs are associated with upcoming or recently completed financing activities. Tracking these accruals provides visibility into near-term cash requirements for capital market transactions.